Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + decitabine + donor lymphocyte infusion
- Development stage
- Unknown
- Lead developer
- Masonic Cancer Center
- Modality
- Small Molecules, Cell Therapies
- Administration
- Intravenous
01
Overview
This combination therapy is a multi-modality regimen being investigated by the Masonic Cancer Center at the University of Minnesota for the treatment of relapsed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) following allogeneic hematopoietic cell transplantation (allo-HCT). The regimen consists of ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor; decitabine, a hypomethylating agent; and donor lymphocyte infusion (DLI), a form of cellular immunotherapy. Decitabine is used to induce the expression of tumor-associated antigens and potentially sensitize leukemia cells to the immune system, while ruxolitinib is intended to modulate the immune environment and reduce the risk of graft-versus-host disease (GVHD). The DLI component provides donor-derived T-cells to elicit a graft-versus-leukemia (GVL) effect, aiming to eradicate residual or relapsed malignant cells.
- Other names
- donor lymphocyte infusion-Masonic Cancer Center, University of Minnesota-acute myeloid leukemia-myelodysplastic syndromes-myelodysplastic/myeloproliferative neoplasmCombined Modality Treatment With Ruxolitinib, Decitabine, and Donor Lymphocyte InfusionRuxolitinib, Decitabine, and DLI
02
Targets
Beyond the preview
Go deeper on ruxolitinib + decitabine + donor lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + decitabine + donor lymphocyte infusion.